Dr. Reddy’s Labs - Sputnik V Receives Expert Panel Nod For Approval: Dolat Capital
A heath worker draws the ‘Sputnik V’ covid vaccine from a vial during a trial in Moscow, Russia. (Photographer: Andrey Rudakov/Bloomberg)

Dr. Reddy’s Labs - Sputnik V Receives Expert Panel Nod For Approval: Dolat Capital

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Dolat Capital Report

Russia’s Covid-19 vaccine Sputnik V has been recommended for use in India by the expert committee.

Dr. Reddy’s Laboratories Ltd. has partnered with Russian Direct Investment Fund to distribute (in India) first 250 million dosages of Sputnik V.

Currently in Phase three in India, Drugs Controller General of India in February 2021 had asked for immunogenicity data before being granted an emergency approval.

Once approved, this would be the third vaccine post Covaxin (Bharat Biotech) and Covishield (Serum Institute of India and Oxford-Astrazeneca) in India.

Click on the attachment to read the full report:

Dolat Capital Dr Reddys Laboratories Company Update.pdf

DISCLAIMER

This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.